Log In
Print
BCIQ
Print
Print this Print this
 

XEN701

  Manage Alerts
Collapse Summary General Information
Company Xenon Pharmaceuticals Inc.
DescriptionAntisense compound that targets hepcidin-hemojuvelin pathway
Molecular Target
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPreclinical
Standard IndicationAnemia
Indication DetailsTreat anemia of inflammation
Regulatory Designation

Partner

Isis Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today